Phosphorus control in peritoneal dialysis patients.

Area of Science:

• Nephrology
• Endocrinology
• Internal Medicine

Background:

• Hyperphosphatemia is a critical predictor of mortality in patients undergoing dialysis.
• Effective phosphate control is essential for managing chronic kidney disease complications.

Purpose of the Study:

• To assess phosphate control status in a large international cohort of patients on chronic peritoneal dialysis (PD).
• To identify clinical and laboratory associations related to phosphate levels in PD patients.

Main Methods:

• A cross-sectional, multicenter study involving 530 patients from 24 centers across Canada, Greece, and Turkey.
• Measured serum levels of calcium, phosphate, intact parathyroid hormone (iPTH), vitamin D metabolites, and alkaline phosphatase.
• Assessed dialysis adequacy parameters including Kt/V, creatinine clearance, and urine output.

Main Results:

• 58% of PD patients achieved recommended serum phosphate levels (3.5-5.5 mg/dL), and 73% had an acceptable calcium-x-phosphate (Ca x P) product (<55 mg²/dL²).
• Serum phosphorus positively correlated with serum albumin and iPTH, and negatively with age.
• Only 24% of patients achieved target iPTH levels, indicating potential challenges in mineral and bone disorder management.

Conclusions:

• Chronic PD, coupled with dietary modifications and phosphate binders, can achieve satisfactory serum phosphorus control in the majority of patients.
• Despite good phosphate control, significant proportions of patients did not meet targets for calcium, Ca x P product, and iPTH.
• Further strategies may be needed to optimize mineral and bone disorder management in PD patients.